EBV LMP-1 negatively regulates expression and pro-apoptotic activity of Par-4 in nasopharyngeal carcinoma cells

Cancer Letters

Volumn 279, Issue 2, 2009, Pages 193-201

  Lee, Jeng Woei ^a   Liu, Po Fan ^a   Hsu, Lee Ping ^b   Chen, Peir Rong ^b   Chang, Chung Hsing ^c   Shih, Wen Ling ^d  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

EBV; LMP 1; Nasopharyngeal carcinoma; Par 4

Indexed keywords

LATENT MEMBRANE PROTEIN 1; PROSTATE APOPTOSIS RESPONSE 4 PROTEIN; PROTEIN; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE REPRESSION; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NASOPHARYNGEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 67349178306     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.01.037     Document Type: Article

References (48)

1. Hildesheim A., and Levine P.H. Etiology of nasopharyngeal carcinoma: a review. Epidemiol. Rev. 15 (1993) 466-485
2. Cho W.C. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol. Cancer 6 (2007) 1-9
3. Rickinson A.B., and Kief E. Fields' Virology. In: Knipe D.M., and Howley P.M. (Eds) (2001), Lippincott Williams & Wilkins, Philadelphia 2575-2627
4. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin. Cancer Biol. 12 (2002) 431-441
5. Tsao S.W., Tramoutanis G., Dawson C.W., Lo A.K., and Huang D.P. The significance of LMP-1 expression in nasopharyngeal carcinoma. Semin. Cancer Biol. 12 (2002) 473-487
6. Wang D., Liebowitz D., and Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43 (1985) 831-840
7. Kaye K.M., Izumi K.M., and Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 90 (1993) 9150-9154
8. Fahraeus R., Rymo L., Rhim J.S., and Klein G. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 345 (1990) 447-449
9. Lee J.W., Lee K.F., Hsu H.Y., Hsu L.P., Shih W.L., Chu Y.C., Hsiao W.T., and Liu P.F. Protein expression and intracellular localization of prostate apoptosis response-4 (Par-4) are associated with apoptosis induction in nasopharyngeal carcinoma cell lines. Cancer Lett. 257 (2007) 252-262
10. Sells S.F., Wood Jr. D.P., Joshi-Barve S.S., Muthukumar S., Jacob R.J., Crist S.A., Humphreys S., and Rangnekar V.M. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ. 5 (1994) 457-466
11. El-Guendy N., and Rangnekar V.M. Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp. Cell Res. 283 (2003) 51-66
12. Gurumurthy S., Goswami A., Vasudevan K.M., and Rangnekar V.M. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol. Cell Biol. 25 (2005) 1146-1161
13. Goswami A., Burikhanov R., de Thonel A., Fujita N., Goswami M., Zhao Y., Eriksson J.E., Tsuruo T., and Rangnekar V.M. Binding and phosphorylation of par-4 by Akt is essential for cancer cell survival. Mol. Cell 20 (2005) 33-44
14. Diaz-Meco M.T., Municio M.M., Frutos S., Sanchez P., Lozano J., Sanz L., and Moscat J. The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 86 1996 (1996) 777-786
15. Johnstone R.W., See R.H., Sells S.F., Wang J., Muthukkumar S., Englert C., Haber D.A., Licht J.D., Sugrue S.P., Roberts T., Rangnekar V.M., and Shi Y. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol. Cell Biol. 16 (1996) 6945-6956
16. Page G., Kögel D., Rangnekar V., and Scheidtmann K.H. Interaction partners of Dlk/ZIP kinase: co-expression of Dlk/ZIP kinase and Par-4 results in cytoplasmic retention and apoptosis. Oncogene 18 (1999) 7265-7273
17. Boosen M., Vetterkind S., Koplin A., Illenberger S., and Preuss U. Par-4-mediated recruitment of Amida to the actin cytoskeleton leads to the induction of apoptosis. Exp. Cell Res. 311 (2005) 177-191
18. Vetterkind S., Illenberger S., Kubicek J., Boosen M., Appel S., Naim H.Y., Scheidtmann K.H., and Preuss U. Binding of Par-4 to the actin cytoskeleton is essential for Par-4/Dlk-medizted apoptosis. Exp. Cell Res. 305 (2005) 392-408
19. Chakraborty M., Qiu S.G., Vasudevan K.M., and Rangnekar V.M. Par-4 drives trafficking and activation of Fas and FasL to induce prostate cancer cell apoptosis and tumor regression. Cancer Res. 61 (2001) 7255-7263
20. El-Guendy N., Zhao Y., Gurumurthy S., Burikhanov R., and Rangnekar V.M. Identification of a unique core domain of Par-4 sufficient for selective apoptosis induction in cancer cells. Mol. Cell Biol. 23 (2003) 5516-5525
21. Pruitt K., Ülkü A.S., Frantz K., Rojas R.J., Muniz-Medina V.M., Rangnekar V.M., Der C.J., and Shields J.M. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J. Biol. Chem. 280 (2005) 23363-23370
22. Ahmed M.M., Sheldon D., Fruitwala M.A., Venkatasubbarao K., Lee E.Y., Gupta S., Wood C., Mohiuddin M., and Strodel W.E. Downregulation of Par-4. a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. Int. J. Cancer 122 (2008) 63-70
23. Qiu S.G., Krishnan S., El-Guendy N., and Rangnekar V.M. Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation. Oncogene 18 (1999) 7115-7123
24. Nalca A.A., Qiu S.G., El-Guendy N., Krishnan S., and Rangnekar V.M. Oncogenic Ras sensitizes cells to apoptosis by Par-4. J. Biol. Chem. 274 (1999) 29976-29983
25. Barradas M., Monjas A., Diaz-Meco M.T., Serrano M., and Moscat J. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. EMBO J. 18 (1999) 6362-6369
26. Garcia-Cao I., Lafuente M.J., Criado L.M., Diaz-Meco M.T., Serrano M., and Moscat J. Genetic inactivation of Par-4 results in hyperactivation of NF-κB and impairment of JNK and p38. EMBO Rep. 4 (2003) 307-312
27. Garcia-Cao I., Duran A., Collado M., Carrascosa M.J., Martin-Caballero J., Flores J.M., Diaz-Meco M.T., Moscat J., and Serrano M. Tumor-suppression activity of the proapoptotic regulator Par-4. EMBO Rep. 6 (2005) 577-583
28. Affar El.B., Luke M.P., Gay F., Calvo D., Sui G., Weiss R.S., Li E., and Shi Y. Targeted ablation of Par-4 reveals a cell type-specific susceptibility to apoptosis-inducing agents. Cancer Res. 66 (2006) 3456-3462
29. Zhao Y., Burikhanov R., Qiu S., Lele S.M., Jennings C.D., Bondada S., Spear B., and Rangnekar V.M. Cancer resistance in transgenic mice expressing the SAC module of Par-4. Cancer Res. 67 (2007) 9176-9185
30. Cook J., Krishnan S., Ananth S., Sells S.F., Shi Y., Walther M.M., Linehan W.M., Sukhatme V.P., Weinstein M.H., and M Rangnekar V. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 18 (1999) 1205-1208
31. Moreno-Bueno G., Fernandez-Marcos P.J., Collado M., Tendero M.J., Rodriguez-Pinilla S.M., Garcia-Cao I., Hardisson D., Diaz-Meco M.T., Moscat J., Serrano M., and Palacios J. Inactivation of the candidate tumor suppressor Par-4 in endometrial cancer. Cancer Res. 67 (2007) 1927-1934
32. Gurumurthy S., and Rangnekar V.M. Par-4 inducible apoptosis in prostate cancer cells. J. Cell Biochem. 91 (2004) 504-512
33. Chang Y., Tung C.H., Huang Y.T., Lu J., Chen J.Y., Tsai, and Tsai C.H. Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes. J. Virol. 73 (1999) 8857-8866
34. Cheema S.K., Mishra S.K., Rangnekar V.M., Tari A.M., Kumar R., and Lopez-Berestein G. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J. Biol. Chem. 278 (2003) 19995-20005
35. Qiu G., Ahmed M., Sells S.F., Mohiuddin M., Weinstein M.H., and Rangnekar V.M. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 18 (1999) 623-631
36. Boehrer S., Chow K.U., Puccetti E., Ruthardt M., Godzisard S., Krapohl A., Schneider B., Hoelzer D., Mitrou P.S., Rangnekar V.M., and Weidmann E. Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia. Hematol. J. 2 (2001) 103-107
37. Boehrer S., Chow K.U., Beske F., Kukoc-Zivojnov N., Puccetti E., Ruthardt M., Baum C., Rangnekar V.M., Hoelzer D., Mitrou P.S., and Weidmann E. In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res. 62 (2002) 1768-1775
38. Verma Y.K., Gangenahalli G.U., Singh V.K., Gupta P., Chandra R., Sharma R.K., and Raj H.G. Cell death regulation by B-cell lymphoma protein. Apoptosis 11 (2006) 459-471
39. De Benedetti A., and Graff J.R. eIF-4E expression and its role in malignancies and metastases. Oncogene 23 (2004) 3189-3199
40. López de Silanes I., Zhan M., Lal A., Yang X., and Gorospe M. Identification of a target RNA motif for RNA-binding protein HuR. Proc. Natl. Acad. Sci. USA 101 (2004) 2987-2992
41. Chang Y., Lee H.H., Chang S.S., Hsu T.Y., Wang P.W., Cahng Y.S., Takada K., and Tsai C.H. Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta. J. Virol. 78 (2004) 13028-13036
42. Liu M.Y., Y Shih Y., Chou S.P., Chen C.J., Sheen T.S., Yang C.S., and Chen J.Y. Antibody against the Epstein-Barr virus BHRF1 protein, a homologue of Bcl-2, in patients with nasopharyngeal carcinoma. J. Med. Virol. 56 (1998) 179-185
43. Aitken A. 14-3-3 Proteins: a historic overview. Semin. Cancer Biol. 16 (2006) 162-172
44. Goswami A., Ranganathan P., and Rangnekar V.M. The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res. 66 (2006) 2889-2892
45. Meller R., Minami M., Cameron J.A., Impey S., Chen D., Lan J.Q., Henshall D.C., and Simon R.P. CREB-mediated Bcl-2 protein expression after ischemic preconditioning. J. Cereb. Blood Flow Metab. 25 (2005) 234-246
46. Kurland J.F., Kodym R., Story M.D., Spurgers K.B., McDonnell T.J., and Myen R.E. NF-κB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J. Biol. Chem. 276 (2001) 45380-45386
47. Heckmen C.A., Mehew J.W., and Boxer L.M. NF-κB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21 (2002) 3898-3908
48. Chen F., Demers L.M., and Shi X. Upstream signal transduction of NF-κB activation. Curr. Drug Targets Inflamm. Allergy 1 (2002) 137-149